In vitro modulatory effects of interleukin-3 on macrophage activation induced by interleukin-2
- 15 March 1993
- Vol. 71 (6), 2076-2081
- https://doi.org/10.1002/1097-0142(19930315)71:6<2076::aid-cncr2820710624>3.0.co;2-i
Abstract
Background. The concomitant activation of macrophage-mediated immunosuppressive events might represent one of the most important biologic factors responsible for the decreased efficacy of cancer immunotherapies, including that of interleukin (IL)-2. In previous studies, the authors observed that the increase in the soluble IL-2 receptor (SIL-2R) and neopterin levels was related to the generation of macrophage-mediated immuno-suppression and associated with a reduced clinical efficacy during IL-2 cancer immunotherapy. Because both cytokines and neurohormones may influence the macrophage system, the current study was done to evaluate the effects of IL-3 and of the pineal hormone melatonin (MLT) on monocyte response to IL-2 administration. Methods. Peripheral blood monocytes were incubated with different concentrations of IL-2, IL-3, and MLT, either alone or in association. Results. SIL-2R, neopterin, and tumor necrosis factor-alpha mean concentrations in the medium significantly increased during incubation with IL-2 at a concentration of 100 Cetus units/ml. IL-3 alone, at a dose of 10 ng/ml, also stimulated tumor necrosis factor release; no effect was found on SIL-2R and neopterin. The IL-2–induced neopterin rise was blocked by a concomitant incubation with IL-3 at a dose of 10 ng/ml. Finally, the concomitant incubation with IL-3 and MLT further inhibited neopterin release and significantly decreased IL-2-induced SIL-2R secretion. Conclusions. These results suggest that IL-3 alone or in association with MLT may modulate macrophage functions during cancer immunotherapy with IL-2 and decrease the IL-2-induced macrophage activation.Keywords
This publication has 15 references indexed in Scilit:
- Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alphaEuropean Journal Of Cancer, 1992
- Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2European Journal of Cancer and Clinical Oncology, 1991
- Human Monocytes in a Long-Term Culture with Interleukin-2 Show High Tumoricidal Activity Against Various Tumor CellsJournal of Immunotherapy, 1991
- The Prognostic Value of Cellular and Serologic Markers in Infection with Human Immunodeficiency Virus Type 1New England Journal of Medicine, 1990
- Pineal Melatonin, Its Fundamental Immunoregulatory Role in Aging and CancerAnnals of the New York Academy of Sciences, 1988
- Cachectin: More Than a Tumor Necrosis FactorNew England Journal of Medicine, 1987
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma.The Journal of Experimental Medicine, 1984
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982
- The Glomerular Permeability Determined by Dextran Clearance Using Sephadex Gel FiltrationScandinavian Journal of Clinical and Laboratory Investigation, 1968